Development of novel ansamycin antibiotics for the treatment of multi-drug resistant Mycobacterium tuberculosis

新型安沙霉素抗生素的开发用于治疗多重耐药结核分枝杆菌

• 批准号: 104745
• 金额: $ 43.6万
• 依托单位: DEMURIS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104745
• 关键词: Development; novel; ansamycin; antibiotics; treatment

Mycobacterium tuberculosis (M.tb) is the causative agent of tuberculosis (TB). The World Health Organisation (WHO) estimates that someone dies from TB every 20 seconds, which is around 1.7 million people per year. There is a growing emergence of M.tb strains which are resistant to first and second line antibiotic treatments. The bacterium can hide in the body remaining dormant for long periods of time, and treatments can last up to one year. New antibiotics that are effective against drug resistant strains are urgently needed. Demuris, in collaboration with Newcastle University, has identified novel antibiotics that are similar to the first-line treatment for TB but, crucially, are active against multi-drug resistant strains. This project will allow us to make a series of closely related compounds, and test these for the range of properties needed for development as an anti-TB drug.

结核分枝杆菌 (M.tb) 是结核病 (TB) 的病原体。世界卫生组织 (WHO) 估计，每 20 秒就有一人死于结核病，每年约有 170 万人死于结核病。对一线和二线抗生素治疗产生耐药性的结核分枝杆菌菌株越来越多。这种细菌可以在体内长期处于休眠状态，治疗可以持续长达一年。迫切需要能够有效对抗耐药菌株的新型抗生素。 Demuris 与纽卡斯尔大学合作，发现了与结核病一线治疗类似的新型抗生素，但最重要的是，它们对多重耐药菌株具有活性。该项目将使我们能够制造一系列密切相关的化合物，并测试它们作为抗结核药物开发所需的一系列特性。